Revisão da literatura sobre as principais drogas vigentes para tratamento da obesidade no Brasil
DOI:
https://doi.org/10.34119/bjhrv6n4-153Keywords:
liraglutida, semaglutida, tirzepatida, orlistate, sibutraminaAbstract
Objetivo: fornecer atualizações sobre as drogas aprovadas no Brasil para o tratamento farmacológico da diabetes, bem como novas drogas promissoras para tal fim, visando ampliar, mas não esgotar, o conhecimento médico sobre tal assunto. Metodologia: revisão narrativa de literatura desenvolvida com base numa pesquisa exploratória de cunho qualitativo concentrada no mês de março de 2023. Resultado: fundamentação teórica através de artigos e estudos atualizados ou anteriores considerados relevantes. Considerações finais: Diversos estudos mostram a eficácia dessas drogas na perda de peso ao comparar com o placebo. Contudo, deve-se respeitar a individualidade de cada paciente conforme o percentual de perda de peso, comorbidades, tolerância e adesão a posologia. A tirzepatida, embora ainda não aprovada no Brasil, vem se mostrando como uma droga segura e eficaz para o tratamento da obesidade em comparação com as outras drogas, com resultados satisfatórios. Além disso, sempre associar o tratamento farmacológico com a prática de atividade física e dieta com restrição calórica para obter melhores desfechos. São necessários novos ensaios clínicos, revisões sistemáticas e metanálise para levantar novas evidências de eficácia e segurança sobre o tema.
References
Khera R, Murad MH, Chandar AK, et al. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA 2016; 315:2424.
Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27:155.
Siebenhofer A, Jeitler K, Horvath K, et al. Long-term effects of weight-reducing drugs in people with hypertension. Cochrane Database Syst Rev 2016; 3:CD007654.
le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 2017; 389:1399.
Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015; 373:11.
Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012; 36:843.
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375:311.
Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA 2021; 325:1414.
Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375:1834.
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021; 384:989.
Yancy WS Jr, Westman EC, McDuffie JR, et al. A randomized trial of a low-carbohydrate diet vs orlistat plus a low-fat diet for weight loss. Arch Intern Med 2010; 170:136.
Leblanc ES, O'Connor E, Whitlock EP, et al. Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:434.
Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21:1288.
Tonstad S, Pometta D, Erkelens DW, et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 1994; 46:405.
Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004; :CD004094.
James, W. P., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rössner, S., Saris, W. H., & Van Gaal, L. F. (2000). Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet (London, England), 356(9248), 2119–2125. https://doi.org/10.1016/s0140-6736(00)03491-7)
Logvinova, O., Kuznetsova, P., Tsvetkova, E., Kremneva, E., Troshina, E., Romantsova, T., Tanashyan, M., & Kolpakova, E. (2020). Study of the effect of sibutramine on central mechanisms of regulation of eating behavior in patients with obesity by means of fMRI. Preliminary results. 22nd European Congress of Endocrinology. Endocrine Abstracts, 70(1). doi: 10.1530/endoabs.70. AEP311
Al-Tahami, B. A. M., Ismail, A. A. A. -., Sanip, Z., Yusoff, Z., Shihabudin, T. M. T. M., Singh, T. S. P., & Rasool, A. H. G. (2017). Metabolic and inflammatory changes with orlistat and sibutramine treatment in obese malaysian subjects. Journal of Nippon Medical School, 84(3), 125-132. doi:10.1272/jnms.84.125
Philip, W., & James, T. (2005). The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. European Heart Journal Supplements, 7, 44–48. https://doi.org/10.1093/eurheartj/sui086
Dedov, I.I., Melnichenko, G. A., Troshina, E. A., Mazurina, N. V., & Galieva, M. O. (2018). Redução de Peso Corporal Associada ao Tratamento de Sibutramina: Resultados Gerais do Ensaio de Atenção Primária à Saúde da PRIMAVERA. Obesity Facts, 11(4), 335-343. https://doi.org/10.1159/000488880
Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 2020; 5.
Reitsma JB, Castro Cabezas M, de Bruin TW, Erkelens DW. Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. Metabolism 1994; 43:293.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022; 387:205.
Wharton S, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Garvey WT. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring). 2023 Mar;31(3):703-715. doi: 10.1002/oby.23673. Epub 2023 Jan 18. PMID: 36655300.
